{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '19.', 'LIST OF REFERENCES', '1.', 'Baena-Cagnani CE and Patel P. Efficacy and long-term safety of mometasone furoate', 'nasal spray in children with perennial allergic rhinitis. Curr Med Res Opin.', '2010;26(9):2047-55.', '2. Barnes ML, Vaidyanathan S, Williamson PA, Lipworth BJ. The minimal clinically', 'important difference in allergic rhinitis. Clin Exp Allergy. 2010;40(2):242-50.', '3.', 'Berger W, Bousquet J, Fox AT, Just J, Muraro A, Nieto A, et al. MP-AzeFlu is more', 'effective than fluticasone propionate for the treatment of allergic rhinitis in children.', 'Allergy. 2016;71(8) 1219-22.', '4. Blaiss MS. Pediatric allergic rhinitis: physical and mental complications. Allergy', 'Asthma Proc. 2008;29(1):1-6.', '5. Brixner D, Meltzer EO, Morland K, Carroll CA, Munzel U, Lipworth BJ. Implication of', 'alternative minimal clinically important difference threshold estimation methods on', 'technology assessment. Int J Technol Assess Health Care. 2016;32(6):371-5.', '6. Code of Federal Regulations (CFR) Title 21, Chapter 1 Food and Drug Administration,', 'Department of Health and Human Services, Subchapter D: Drugs for Human Use Part', '312: Investigational New Drug Application, Subpart A: General Provisions, $312.6', 'Labeling of an investigational new drug, 2017. Available at:', 'ttps://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=312', '7. DYMISTA USPI (2015). US Prescribing Information: DYMISTA (azelastine', 'hydrochloride and fluticasone propionate) Nasal Spray; Initial U.S. Approval: 2012;', 'Revised: February 2015.', '8. FDA Draft Guidance for Industry. Allergic Rhinitis: Clinical Development Programs for', 'Drug Products April 2000, Available at: http://www.fda.gov/cder/guidance/index.htm', '9. FDA Draft Allergic Rhinitis Guidance (2016). FDA Guidance for Industry - Allergic', 'Rhinitis: Developing Drug Products for Treatment. Draft Guidance, Feb 2016.', 'Available at https://www.fda.gov/downloads/drugs/guidances/ucm071293.pdf', '10. GSP 301 IB update 4.0 (2017). Investigational Brochure, Olopatadine Hydrochloride and', 'Mometasone Furoate Aqueous Nasal Spray.', '11. Jauregui I, Mullol J, Davila I, Ferrer M, Bartra J, del Cuvillo A, et al. Allergic rhinitis and', 'school performance. J Investig Allergol Clin Immunol. 2009;19(Suppl 1):32-9.', '12. Juniper EF, Howland WC, Roberts NB, Thompson AK, King DR. Measuring quality of', 'life in children with rhinoconjunctivitis. J Allergy Clin Immunol. 998;101:163-170.', '13. Kaliner MA, Oppenheimer J, Farrar JR. Comprehensive review of olopatadine: the', 'molecule and its clinical entities. Allergy Asthma Proc. 2010;31(2):112-9.', '14. Lai L, Casale TB, Stokes J. Pediatric allergic rhinitis: treatment. Immunol Allergy Clin', 'North Am. 2005;25(2):283-99', 'Glenmark', 'CONFIDENTIAL', 'Page 72 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '15. Meltzer EO, Blaiss M, Fairchild CJ. Comprehensive report of olopatadine 0.6% nasal', 'spray as treatment for children with seasonal allergic rhinitis. Allergy Asthma Proc.', '2011;32(3):213-20.', '16. Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, et al. Burden of', 'allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin', 'Immunol. 2009;124(Suppl 3 3): S43-70.', '17. Meltzer EO, Wallace D, Dykewicz M, Shneyer L. Minimal clinically important', 'difference (MCID) in allergic rhinitis: Agency for Healthcare Research and Quality or', 'Anchor-Based Thresholds? J Allergy Clin Immunol Pract. 2016;4(4): 682-8 e6.', '18. Min Y-G. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy', 'Asthma Immunol Res. 2010;2(2):65-76', '19. Naclerio RM, Bachert C, Baraniuk JN. Pathophysiology of nasal congestion. Int J Gen', 'Med. 2010;3:47-57', '20. NDA Number 20-762 (2014). Pharmacological review of Nasonex nasal spray', '(mometasone furoate monohydrate nasal spray). Center for Drug Evaluation and', 'Research.', '21. NDA Number 21-861 (2008). Pharmacology/Toxicology review and evaluation of', 'Patanase nasal spray. Center for Drug Evaluation and Research.', '22. Nasser M, Fedorowicz Z, Aljufairi H, McKerrow W. Antihistamines used in addition to', 'topical nasal steroids for intermittent and persistent allergic rhinitis in children. Cochrane', 'Database Syst Rev. 2010;7:CD006989.', '23. NASONEX USPI (2013). US Prescribing Information: NASONEX (mometasone', 'furoate) Nasal Spray; Initial U.S. Approval: 1997; Revised: March 2013.', '24. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007; 28(1): 3-9.', '25. Okano M. Mechanisms and clinical implications of glucocorticosteroids in the treatment', 'of allergic rhinitis. Clin Exp Immunol. 2009;158(2):164-73.', '26. PATANASE USPI (2012). US Prescribing Information: PATANASE (olopatadine', 'hydrochloride) Nasal Spray; Initial U.S. Approval: 1996; Revised: February 2012.', '27. Prenner BM, Schenkel E. Allergic rhinitis: treatment based on patient profiles. Am J', 'Med. 2006;119(3):230-7.', '28. Raphael GD, Berger WE, Prenner BM, Finn AF Jr, Kelley L, Tantry SK. Efficacy, safety,', 'and optimal dose selection of beclomethasone dipropionate nasal aerosol for seasonal', 'allergic rhinitis in adolescents and adults. Curr Med Res Opin. 2013;29(10):1329-40.', \"29. Rosenwasser LJ, O'Brien T, Weyne J. Mast cell stabilization and anti-histamine effects of\", 'olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Curr Med', 'Res Opin. 2005;21(9):1377-87.', '30. Shapiro G, Nassef M. Rhinitis: A practical approach. RAD: Respiratory and Allergic', 'Disease Foundation. Release date: October 2005. Sponsored by Postgraduate Institute', 'Glenmark', 'CONFIDENTIAL', 'Page 73 of 90']\n\n###\n\n", "completion": "END"}